


In the Claims:

Please amend claims 14 and 16 as follows.

1. (Previously Presented) A compound of formula (I):



wherein:

- 5 R<sup>1</sup> is selected from the group consisting of H, alkyl, alkenyl, alkynyl, -C(O)R<sup>7</sup>,  
-CO<sub>2</sub>R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>8</sup>, -C(O)N(R<sup>7</sup>)OR<sup>8</sup>, -C(O)N(R<sup>7</sup>)-R<sup>2</sup>-OR<sup>8</sup>, -C(O)N(R<sup>7</sup>)-Ph,  
-C(O)N(R<sup>7</sup>)-R<sup>2</sup>-Ph, -C(O)N(R<sup>7</sup>)C(O)R<sup>8</sup>, -C(O)N(R<sup>7</sup>)CO<sub>2</sub>R<sup>8</sup>,  
-C(O)N(R<sup>7</sup>)C(O)NR<sup>7</sup>R<sup>8</sup>, -C(O)N(R<sup>7</sup>)S(O)<sub>2</sub>R<sup>8</sup>, -R<sup>2</sup>-OR<sup>7</sup>, -R<sup>2</sup>-O-C(O)R<sup>7</sup>,  
-C(S)R<sup>7</sup>, -C(S)NR<sup>7</sup>R<sup>8</sup>, -C(S)N(R<sup>7</sup>)-Ph, -C(S)N(R<sup>7</sup>)-R<sup>2</sup>-Ph, -R<sup>2</sup>-SR<sup>7</sup>,  
10 -C(=NR<sup>7</sup>)NR<sup>7</sup>R<sup>8</sup>, -C(=NR<sup>7</sup>)N(R<sup>8</sup>)-Ph, -C(=NR<sup>7</sup>)N(R<sup>8</sup>)-R<sup>2</sup>-Ph, -R<sup>2</sup>-NR<sup>7</sup>R<sup>8</sup>, -CN,  
-OR<sup>7</sup>, -S(O)<sub>2</sub>R<sup>7</sup>, -S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, -S(O)<sub>2</sub>N(R<sup>7</sup>)-Ph, -S(O)<sub>2</sub>N(R<sup>7</sup>)-R<sup>2</sup>-Ph, -NR<sup>7</sup>R<sup>8</sup>,  
-N(R<sup>7</sup>)-Ph, -N(R<sup>7</sup>)-R<sup>2</sup>-Ph, -N(R<sup>7</sup>)-SO<sub>2</sub>R<sup>8</sup> and tetrazole;

Ph is phenyl optionally substituted from 1 to 3 times with a substituent selected from  
the group consisting of halo, alkyl, -OH, -R<sup>2</sup>-OH, -O-alkyl, -R<sup>2</sup>-O-alkyl, -NH<sub>2</sub>,  
15 -N(H)alkyl, -N(alkyl)<sub>2</sub>, -CN and -N<sub>3</sub>;

Het is a 5-7 membered heterocycle having 1, 2, 3 or 4 heteroatoms selected from N,  
O and S, or a 5-6 membered heteroaryl having 1, 2, 3 or 4 heteroatoms  
selected from N, O and S, each optionally substituted from 1 to 2 times with a  
substituent selected from the group consisting of halo, alkyl, oxo, -OH,  
20 -R<sup>2</sup>-OH, -O-alkyl, -R<sup>2</sup>-O-alkyl, -NH<sub>2</sub>, -N(H)alkyl, -N(alkyl)<sub>2</sub>, -CN and -N<sub>3</sub>;

Q<sup>1</sup> is a group of formula:  $-(R^2)_a-(Y^1)_b-(R^2)_c-R^3$

a, b and c are the same or different and are each independently 0 or 1 and at least  
one of a or b is 1;

n is 0, 1, 2, 3 or 4;


- 25 Q<sup>2</sup> is a group of formula:  $-(R^2)_{aa}-(Y^2)_{bb}-(R^2)_{cc}-R^4$

aa, bb and cc are the same or different and are each independently 0 or 1;

each  $Y^1$  and  $Y^2$  is the same or different and is independently selected from the group consisting of  $-O-$ ,  $-S(O)_r-$ ,  $-N(R^7)-$ ,  $-C(O)-$ ,  $-OC(O)-$ ,  $-CO_2-$ ,  $-C(O)N(R^7)-$ ,  $-C(O)N(R^7)S(O)_2-$ ,  $-OC(O)N(R^7)-$ ,  $-OS(O)_2-$ ,  $-S(O)_2N(R^7)-$ ,  $-S(O)_2N(R^7)C(O)-$ ,  $-N(R^7)S(O)_2-$ ,  $-N(R^7)C(O)-$ ,  $-N(R^7)CO_2-$  and  $-N(R^7)C(O)N(R^7)-$ ;

each  $R^2$  is the same or different and is independently selected from the group consisting of alkylene, alkenylene and alkynylene;

each  $R^3$  and  $R^4$  is the same or different and is each independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl,  $-C(O)R^7$ ,  $-C(O)NR^7R^8$ ,  $-CO_2R^7$ ,  $-C(S)R^7$ ,  $-C(S)NR^7R^8$ ,  $-C(=NR^7)R^8$ ,  $-C(=NR^7)NR^7R^8$ ,  $-CR^7=N-OR^7$ ,  $-OR^7$ ,  $-S(O)_rR^7$ ,  $-S(O)_2NR^7R^8$ ,  $-NR^7R^8$ ,  $-N(R^7)C(O)R^8$ ,  $-N(R^7)S(O)_2R^8$ ,  $-NO_2$ ,  $-CN$ ,  $-N_3$  and a group of formula (ii):



ii

wherein:

Ring A is selected from the group consisting of  $C_{5-10}$ cycloalkyl,  $C_{5-10}$ cycloalkenyl, aryl, 5-10 membered heterocycle having 1, 2 or 3 heteroatoms selected from N, O and S and 5-10 membered heteroaryl having 1, 2 or 3 heteroatoms selected from N, O and S

each d is 0 or 1;

e is 0, 1, 2, 3 or 4;

each  $R^6$  is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ph, Het,  $-CH(OH)-R^2-OH$ ,  $-C(O)R^7$ ,  $-CO_2R^7$ ,  $-CO_2-R^2-Ph$ ,  $-CO_2-R^2-Het$ ,  $-C(O)NR^7R^8$ ,  $-C(O)N(R^7)C(O)R^7$ ,  $-C(O)N(R^7)CO_2R^7$ ,  $-C(O)N(R^7)C(O)NR^7R^8$ ,  $-C(O)N(R^7)S(O)_2R^7$ ,  $-C(S)R^7$ ,  $-C(S)NR^7R^8$ ,  $-C(=NR^7)R^8$ ,  $-C(=NR^7)NR^7R^8$ ,  $-CR^7=N-OR^8$ ,  $=O$ ,  $-OR^7$ ,  $-OC(O)R^7$ ,  $-OC(O)Ph$ ,  $-OC(O)Het$ ,  $-OC(O)NR^7R^8$ ,  $-O-R^2-S(O)_2R^7$ ,  $-S(O)_rR^7$ ,  $-S(O)_2NR^7R^8$ ,  $-S(O)_2Ph$ ,  $-S(O)_2Het$ ,  $-NR^7R^8$ ,  $-N(R^7)C(O)R^8$ ,  $-N(R^7)CO_2R^8$ ,  $-N(R^7)-R^2-CO_2R^8$ ,  $-N(R^7)C(O)NR^7R^8$ ,  $-N(R^7)-R^2-C(O)NR^7R^8$ ,  $-N(R^7)C(O)Ph$ ,  $-N(R^7)C(O)Het$ ,  $-N(R^7)Ph$ ,  $-N(R^7)Het$ ,  $-N(R^7)C(O)NR^7-R^2-NR^7R^8$ ,  $-N(R^7)C(O)N(R^7)Ph$ ,  $-N(R^7)C(O)N(R^7)Het$ ,  $-N(R^7)C(O)N(R^7)-R^2-Het$ ,  $-N(R^7)S(O)_2R^8$ ,  $-N(R^7)-R^2-S(O)_2R^8$ ,  $-NO_2$ ,  $-CN$  and  $-N_3$ ;

wherein when  $Q^1$  is defined where b is 1 and c is 0,  $R^3$  is not halo,  $-C(O)R^7$ ,

-C(O)NR<sup>7</sup>R<sup>8</sup>, -CO<sub>2</sub>R<sup>7</sup>, -C(S)R<sup>7</sup>, -C(S)NR<sup>7</sup>R<sup>8</sup>, -C(=NR<sup>7</sup>)R<sup>8</sup>, -C(=NR<sup>7</sup>)NR<sup>7</sup>R<sup>8</sup>,  
-CR<sup>7</sup>=N-OR<sup>7</sup>, -OR<sup>7</sup>, -S(O)<sub>f</sub>R<sup>7</sup>, -S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, -NR<sup>7</sup>R<sup>8</sup>, -N(R<sup>7</sup>)C(O)R<sup>8</sup>,  
-N(R<sup>7</sup>)S(O)<sub>2</sub>R<sup>8</sup>, -NO<sub>2</sub>, -CN or -N<sub>3</sub>;

65 wherein when Q<sup>2</sup> is defined where bb is 1 and cc is 0, R<sup>4</sup> is not halo, -C(O)R<sup>7</sup>,  
-C(O)NR<sup>7</sup>R<sup>8</sup>, -CO<sub>2</sub>R<sup>7</sup>, -C(S)R<sup>7</sup>, -C(S)NR<sup>7</sup>R<sup>8</sup>, -C(=NR<sup>7</sup>)R<sup>8</sup>, -C(=NR<sup>7</sup>)NR<sup>7</sup>R<sup>8</sup>,  
-CR<sup>7</sup>=N-OR<sup>7</sup>, -OR<sup>7</sup>, -S(O)<sub>f</sub>R<sup>7</sup>, -S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, -NR<sup>7</sup>R<sup>8</sup>, -N(R<sup>7</sup>)C(O)R<sup>8</sup>,  
-N(R<sup>7</sup>)S(O)<sub>2</sub>R<sup>8</sup>, -NO<sub>2</sub>, -CN or -N<sub>3</sub>;

R<sup>5</sup> is selected from the group consisting of H, halo, alkyl, cycloalkyl, OR<sup>7</sup>, -S(O)<sub>f</sub>R<sup>7</sup>,  
70 -NR<sup>7</sup>R<sup>8</sup>, -NHC(O)R<sup>7</sup>, -NHC(O)NR<sup>7</sup>R<sup>8</sup> and -NHS(O)<sub>2</sub>R<sup>7</sup>;

f is 0, 1 or 2; and

each R<sup>7</sup> and each R<sup>8</sup> are the same or different and are each independently selected  
from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and  
cycloalkenyl;

75 wherein when R<sup>1</sup> is -CO<sub>2</sub>CH<sub>3</sub> and n is 0, Q<sup>1</sup> is not -OH;  
or a pharmaceutically acceptable salt thereof.

2. (Original) The compound according to claim 1, wherein R<sup>1</sup> is selected  
from the group consisting of -C(O)R<sup>7</sup>, -CO<sub>2</sub>R<sup>7</sup> and -C(O)NR<sup>7</sup>R<sup>8</sup>.

3. (Original) The compound according to claim 1, wherein R<sup>1</sup> is selected  
from the group consisting of -CO<sub>2</sub>R<sup>7</sup> and -C(O)NR<sup>7</sup>R<sup>8</sup>.


4. (Previously Presented) The compound according to claim 1, wherein b  
is 1.

5. (Previously Presented) The compound according to claim 1, wherein Q<sup>1</sup>  
is defined wherein b is 1 and Y<sup>1</sup> is selected from -O-, -N(R<sup>7</sup>)-, -C(O)-, -OC(O)-,  
-C(O)N(R<sup>7</sup>)-, -OS(O)<sub>2</sub>-, -S(O)<sub>2</sub>N(R<sup>7</sup>)-, -N(R<sup>7</sup>)SO<sub>2</sub>- and -N(R<sup>7</sup>)C(O)-.

6. (Original) The compound according to claim 5, wherein Q<sup>1</sup> is defined  
wherein b is 1 and Y<sup>1</sup> is selected from -O-, -N(R<sup>7</sup>)-, -C(O)-, -OS(O)<sub>2</sub>-, -N(R<sup>7</sup>)SO<sub>2</sub>-  
and -N(R<sup>7</sup>)C(O)-.


7. (Previously Presented) The compound according to claim 1, wherein c  
is 1.

8. (Previously Presented) The compound according to claim 1, wherein  $R^3$  is selected from the group consisting of H, alkyl, alkenyl, alkynyl, and a group of formula (ii):




9. (Previously Presented) The compound according to claim 1, wherein  $R^3$  is a group of formula (ii) and Ring A is selected from aryl, 5-10 membered heterocycle having 1, 2 or 3 heteroatoms selected from N, O and S and 5-10 membered heteroaryl having 1, 2 or 3 heteroatoms selected from N, O and S.

10. (Previously Presented) The compound according to claim 1, wherein  $R^3$  is a group of formula (ii) and Ring A is selected from the group consisting of cycloalkyl, tetrahydropyran, tetrahydrofuran, morpholine, piperidine, phenyl, naphthyl, thiophene, furan, pyrrole, pyrrolidine, pyrrolidinone, imidazole, benzofuran, benzimidazole, pyridyl,



11. (Previously Presented) The compound according to claim 1, wherein  $Q^1$  is selected from the group consisting of



12. (Previously Presented) The compound according to claim 1, wherein  $R^3$  is a group of formula (ii) and e is 0, 1, 2 or 3.

13. (Previously Presented) The compound according to claim 1, wherein  $R^3$  is a group of formula (ii) and d is 0.


14. (Currently Amended) The compound according to claim 1, wherein ~~wherein~~  $R^3$  is a group of formula (ii) and each  $R^6$  is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl,  $-OR^7$ ,  $-S(O)_fR^7$ ,  $-SO_2NR^7R^8$ ,  $-NR^7R^8$ ,  $-N(R^7)S(O)_2R^8$ ,  $-NO_2$  and  $-CN$ .

15. (Previously Presented) The compound according to claim 1, wherein n is 0, 1 or 2.

16. (Currently Amended) The compound according to claim 1, wherein  $Q^2$  is defined wherein bb is 1 and  $Y^2$  is  $-O-$ ,  $-S(O)_f-$ ,  $-N(R^7)-$ ,  $-C(O)-$ ,  $-OC(O)-$ ,  $-CO_2-$ ,  $-C(O)N(R^7)-$ ,  $-OS(O)_2-$ ,  $-N(R^7)S(O)_2-$ ,  $-N(R^7)C(O)-$ ,  $-N(R^7)CO_2-$  ~~and or~~ or  $-N(R^7)C(O)N(R^7)-$ .

17. (Previously Presented) The compound according to claim 1, wherein cc is 1.

18. (Previously Presented) The compound according to claim 1, wherein each  $R^4$  is the same or different and is independently selected from the group consisting of H, halo, alkyl, alkenyl, alkynyl,  $-C(O)NR^7R^8$ ,  $-OR^7$ ,  $-S(O)_fR^7$ ,  $-S(O)_2NR^7R^8$ ,  $-NR^7R^8$ ,  $-N(R^7)C(O)R^8$ ,  $-N(R^7)S(O)_2R^8$ ,  $-NO_2$ ,  $-CN$ ,  $-N_3$  and a group of formula (ii):



19. (Previously Presented) The compound according to claim 1, wherein  $R^5$  is H, halo, alkyl or  $-NR^7R^8$ .

20. (Previously Presented) A compound selected from the group consisting of:
- 5 5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-([2-(trifluoromethyl)benzyl]oxy)thiophene-2-carboxamide;
- 5-(5-(Methyloxy)-6-([2-(4-methyl-1-piperazinyl)ethyl]oxy)-1*H*-benzimidazol-1-yl)-3-([2-(trifluoromethyl)phenyl]methyl)oxy)-2-thiophenecarboxamide;
- 3-[1-(2-Chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;
- 10 5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-[1-(2-methylphenyl)ethoxy] thiophene-2-carboxamide;
- 5-(5-Amino-1*H*-benzimidazol-1-yl)-3-[1-(2-chlorophenyl)ethoxy]thiophene-2-carboxamide;
- 5-{6-([4-Piperidinylmethyl]oxy)-1*H*-benzimidazol-1-yl}-3-([2-(trifluoromethyl)phenyl]methyl)oxy)-2-thiophenecarboxamide;
- 15 5-(6-(Methyloxy)-5-([3-(2-oxo-1-pyrrolidinyl)propyl]oxy)-1*H*-benzimidazol-1-yl)-3-([2-(trifluoromethyl)phenyl]methyl)oxy)-2-thiophenecarboxamide;
- 5-[6-([3-(Dimethylamino)propyl]oxy)-5-(methyloxy)-1*H*-benzimidazol-1-yl]-3-([2-(trifluoromethyl)phenyl]methyl)oxy)-2-thiophenecarboxamide;
- 20 5-(5-(Methyloxy)-6-([2-(4-morpholinyl)ethyl]oxy)-1*H*-benzimidazol-1-yl)-3-([2-(trifluoromethyl)phenyl]methyl)oxy)-2-thiophenecarboxamide;
- 5-[6-(2-Morpholin-4-ylethoxy)-1*H*-benzimidazol-1-yl]-3-([2-(trifluoromethyl)benzyl]oxy)thiophene-2-carboxamide;
- 5-[6-(2-Pyrrolidin-1-ylethoxy)-1*H*-benzimidazol-1-yl]-3-([2-(trifluoromethyl)benzyl]oxy)thiophene-2-carboxamide;
- 25 5-[5-Fluoro-6-(2-morpholin-4-ylethoxy)-1*H*-benzimidazol-1-yl]-3-([2-(trifluoromethyl)benzyl]oxy)thiophene-2-carboxamide;
- 5-[6-(Methylsulfonyl)-1*H*-benzimidazol-1-yl]-3-([2-(trifluoromethyl)benzyl]oxy)thiophene-2-carboxamide;
- 30 3-[(3-Bromopyridin-4-yl)methoxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;
- 5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-([2-(trifluoromethoxy)benzyl]oxy)thiophene-2-carboxamide;
- 3-([2-(Difluoromethoxy)benzyl]oxy)-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;
- 35

- 3-[(2-Chloropyridin-3-yl)methoxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;  
5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-[(2-fluoropyridin-3-yl)methoxy]thiophene-2-carboxamide;  
40 3-[(2-Aminopyridin-4-yl)methoxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;  
3-[(6-Chloro-1,3-benzodioxol-5-yl)methoxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;  
5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-[(2-nitrobenzyl)oxy]thiophene-2-  
45 carboxamide;  
3-[(3-Aminobenzyl)oxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;  
5-(6-Bromo-1*H*-benzimidazol-1-yl)-3-[[2-(trifluoromethyl)benzyl]oxy]thiophene-2-carboxamide;  
50 3-[(2,6-Dichlorobenzyl)oxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;  
3-[(2-Bromobenzyl)oxy]-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thiophene-2-carboxamide;  
5-(5,6-Dimethoxy-1*H*-benzimidazol-1-yl)-3-[(2-formylbenzyl)oxy]thiophene-2-  
55 carboxamide;  
5-(1*H*-Benzimidazol-1-yl)-3-[[2-(trifluoromethyl)benzyl]oxy]thiophene-2-carboxamide;  
5-(1*H*-Benzimidazol-1-yl)-3-[(2-nitrobenzyl)oxy]thiophene-2-carboxamide;  
5-(6-Methoxy-1*H*-benzimidazol-1-yl)-3-[[2-(trifluoromethyl)benzyl]oxy]thiophene-2-carboxamide;  
60 2-(Aminocarbonyl)-5-(5,6-dimethoxy-1*H*-benzimidazol-1-yl)thien-3-yl 2-methylbenzenesulfonate  
and pharmaceutically acceptable salts thereof.

21. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

22. (Cancelled)

23. (Original) The pharmaceutical composition according to claim 21 further comprising a chemotherapeutic agent.

24. (Cancelled)

25. (Previously Presented) A method for treating a susceptible neoplasm in an animal, said method comprising administering to the animal a therapeutically effective amount of a compound according to claim 1.

26. (Original) The method according to claim 25, wherein said susceptible neoplasm is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, leukemia, endometrial cancer, melanoma, ovarian cancer, pancreatic cancer, squamous carcinoma, carcinoma of the head and neck, and esophageal carcinoma.


27. (Previously Presented) A method for treating a condition characterized by inappropriate cellular proliferation in an animal, said method comprising administering to the animal a therapeutically effective amount of a compound according to claim 1.

28. (Previously Presented) A method for inhibiting proliferation of a cell, said method comprising contacting the cell with an amount of a compound according to claim 1 sufficient to inhibit proliferation of the cell.


29. (Previously Presented) A method for inhibiting mitosis in a cell, said method comprising administering to the cell an amount of a compound according to claim 1 sufficient to inhibit mitosis in the cell.



30. (Previously Presented) A process for preparing a compound according to claim 1, said process comprising reacting a compound of formula (III):




5 with a compound of formula (IV):



wherein R¹⁰ is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and suitable carboxylic acid protecting groups.

31-42. (Cancelled)

43. (Previously Presented) A compound of formula (Ib):



wherein:

5 R¹ is selected from the group consisting of H, alkyl, alkenyl, alkynyl, -C(O)R⁷, -CO₂R⁷, -C(O)NR⁷R⁸, -C(O)N(R⁷)OR⁸, -C(O)N(R⁷)-R²-OR⁸, -C(O)N(R⁷)-Ph, -C(O)N(R⁷)-R²-Ph, -C(O)N(R⁷)C(O)R⁸, -C(O)N(R⁷)CO₂R⁸, -C(O)N(R⁷)C(O)NR⁷R⁸, -C(O)N(R⁷)S(O)₂R⁸, -R²-OR⁷, -R²-O-C(O)R⁷, -C(S)R⁷, -C(S)NR⁷R⁸, -C(S)N(R⁷)-Ph, 10 -C(S)N(R⁷)-R²-Ph, -R²-SR⁷, -C(=NR⁷)NR⁷R⁸, -C(=NR⁷)N(R⁸)-Ph, -C(=NR⁷)N(R⁸)-R²-Ph, -R²-NR⁷R⁸, -CN, -OR⁷, -S(O)R⁷, -S(O)₂NR⁷R⁸, -S(O)₂N(R⁷)-Ph, -S(O)₂N(R⁷)-R²-Ph, -NR⁷R⁸, N(R⁷)-Ph, -N(R⁷)-R²-Ph, -N(R⁷)-SO₂R⁸ and tetrazole;

15 Ph is phenyl optionally substituted from 1 to 3 times with a substituent selected from the group consisting of halo, alkyl, -OH, -R²-OH, -O-alkyl, -R²-O-alkyl, -NH₂, -N(H)alkyl, -N(alkyl)₂, -CN and -N₃;

Het is a 5-7 membered heterocycle having 1, 2, 3 or 4 heteroatoms selected from N, O and S, or a 5-6 membered heteroaryl having 1, 2, 3 or 4 heteroatoms

selected from N, O and S, each optionally substituted from 1 to 2 times with a  
20 substituent selected from the group consisting of halo, alkyl, oxo, -OH,  
-R<sup>2</sup>-OH, -O-alkyl, -R<sup>2</sup>-O-alkyl, -NH<sub>2</sub>, -N(H)alkyl, -N(alkyl)<sub>2</sub>, -CN and -N<sub>3</sub>;

n is 0, 1, 2, 3 or 4;


Q<sup>2</sup> is a group of formula:  $-(R^2)_{aa}-(Y^2)_{bb}-(R^2)_{cc}-R^4$

aa, bb and cc are the same or different and are each independently 0 or 1;

25 each Y<sup>2</sup> is the same or different and is independently selected from the group  
consisting of -O-, -S(O)<sub>r</sub>-, -N(R<sup>7</sup>)-, -C(O)-, -OC(O)-, -CO<sub>2</sub>-, -C(O)N(R<sup>7</sup>)-,  
-C(O)N(R<sup>7</sup>)S(O)<sub>2</sub>-, -OC(O)N(R<sup>7</sup>)-, -OS(O)<sub>2</sub>-, -S(O)<sub>2</sub>N(R<sup>7</sup>)-, -S(O)<sub>2</sub>N(R<sup>7</sup>)C(O)-,  
-N(R<sup>7</sup>)S(O)<sub>2</sub>-, -N(R<sup>7</sup>)C(O)-, -N(R<sup>7</sup>)CO<sub>2</sub>- and -N(R<sup>7</sup>)C(O)N(R<sup>7</sup>)-;

each R<sup>2</sup> is the same or different and is independently selected from the group  
30 consisting of alkylene, alkenylene and alkynylene;

each R<sup>4</sup> is the same or different and is each independently selected from the group  
consisting of H, halo, alkyl, alkenyl, alkynyl, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>8</sup>, -CO<sub>2</sub>R<sup>7</sup>,  
-C(S)R<sup>7</sup>, -C(S)NR<sup>7</sup>R<sup>8</sup>, -C(=NR<sup>7</sup>)R<sup>8</sup>, -C(=NR<sup>7</sup>)NR<sup>7</sup>R<sup>8</sup>, -CR<sup>7</sup>=N-OR<sup>7</sup>, -OR<sup>7</sup>,  
-S(O)<sub>r</sub>R<sup>7</sup>, -S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, -NR<sup>7</sup>R<sup>8</sup>, -N(R<sup>7</sup>)C(O)R<sup>8</sup>, -N(R<sup>7</sup>)S(O)<sub>2</sub>R<sup>8</sup>, -NO<sub>2</sub>, -CN, -N<sub>3</sub>  
35 and a group of formula (ii):



wherein:

Ring A is selected from the group consisting of C<sub>5-10</sub>cycloalkyl,  
C<sub>5-10</sub>cycloalkenyl, aryl, 5-10 membered heterocycle having 1, 2 or 3  
40 heteroatoms selected from N, O and S and 5-10 membered heteroaryl  
having 1, 2 or 3 heteroatoms selected from N, O and S

each d is 0 or 1;

e is 0, 1, 2, 3 or 4;

each R<sup>6</sup> is the same or different and is independently selected from the group  
45 consisting of H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,  
Ph, Het, -CH(OH)-R<sup>2</sup>-OH, -C(O)R<sup>7</sup>, -CO<sub>2</sub>R<sup>7</sup>, -CO<sub>2</sub>-R<sup>2</sup>-Ph, -CO<sub>2</sub>-R<sup>2</sup>-Het,  
-C(O)NR<sup>7</sup>R<sup>8</sup>, -C(O)N(R<sup>7</sup>)C(O)R<sup>7</sup>, -C(O)N(R<sup>7</sup>)CO<sub>2</sub>R<sup>7</sup>,  
-C(O)N(R<sup>7</sup>)C(O)NR<sup>7</sup>R<sup>8</sup>, -C(O)N(R<sup>7</sup>)S(O)<sub>2</sub>R<sup>7</sup>, -C(S)R<sup>7</sup>, -C(S)NR<sup>7</sup>R<sup>8</sup>,  
-C(=NR<sup>7</sup>)R<sup>8</sup>, -C(=NR<sup>7</sup>)NR<sup>7</sup>R<sup>8</sup>, -CR<sup>7</sup>=N-OR<sup>8</sup>, =O, -OR<sup>7</sup>, -OC(O)R<sup>7</sup>,  
50 -OC(O)Ph, -OC(O)Het, -OC(O)NR<sup>7</sup>R<sup>8</sup>, -O-R<sup>2</sup>-S(O)<sub>2</sub>R<sup>7</sup>, -S(O)<sub>r</sub>R<sup>7</sup>,

55  
-S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, -S(O)<sub>2</sub>Ph, -S(O)<sub>2</sub>Het, -NR<sup>7</sup>R<sup>8</sup>, -N(R<sup>7</sup>)C(O)R<sup>8</sup>,  
-N(R<sup>7</sup>)CO<sub>2</sub>R<sup>8</sup>, -N(R<sup>7</sup>)-R<sup>2</sup>-CO<sub>2</sub>R<sup>8</sup>, -N(R<sup>7</sup>)C(O)NR<sup>7</sup>R<sup>8</sup>,  
-N(R<sup>7</sup>)-R<sup>2</sup>-C(O)NR<sup>7</sup>R<sup>8</sup>, -N(R<sup>7</sup>)C(O)Ph, -N(R<sup>7</sup>)C(O)Het, -N(R<sup>7</sup>)Ph,  
-N(R<sup>7</sup>)Het, -N(R<sup>7</sup>)C(O)NR<sup>7</sup>-R<sup>2</sup>-NR<sup>7</sup>R<sup>8</sup>, -N(R<sup>7</sup>)C(O)N(R<sup>7</sup>)Ph,  
-N(R<sup>7</sup>)C(O)N(R<sup>7</sup>)Het, -N(R<sup>7</sup>)C(O)N(R<sup>7</sup>)-R<sup>2</sup>-Het, -N(R<sup>7</sup>)S(O)<sub>2</sub>R<sup>8</sup>,  
-N(R<sup>7</sup>)-R<sup>2</sup>-S(O)<sub>2</sub>R<sup>8</sup>, -NO<sub>2</sub>, -CN and -N<sub>3</sub>;

wherein when Q<sup>2</sup> is defined where bb is 1 and cc is 0, R<sup>4</sup> is not halo, -C(O)R<sup>7</sup>,  
-C(O)NR<sup>7</sup>R<sup>8</sup>, -CO<sub>2</sub>R<sup>7</sup>, -C(S)R<sup>7</sup>, -C(S)NR<sup>7</sup>R<sup>8</sup>, -C(=NR<sup>7</sup>)R<sup>8</sup>, -C(=NR<sup>7</sup>)NR<sup>7</sup>R<sup>8</sup>,  
-CR<sup>7</sup>=N-OR<sup>7</sup>, -OR<sup>7</sup>, -S(O)<sub>f</sub>R<sup>7</sup>, -S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, -NR<sup>7</sup>R<sup>8</sup>, -N(R<sup>7</sup>)C(O)R<sup>8</sup>,  
60 -N(R<sup>7</sup>)S(O)<sub>2</sub>R<sup>8</sup>, -NO<sub>2</sub>, -CN or -N<sub>3</sub>;

R<sup>5</sup> is selected from the group consisting of H, halo, alkyl, cycloalkyl, OR<sup>7</sup>, -S(O)<sub>f</sub>R<sup>7</sup>,  
-NR<sup>7</sup>R<sup>8</sup>, -NHC(O)R<sup>7</sup>, -NHC(O)NR<sup>7</sup>R<sup>8</sup> and -NHS(O)<sub>2</sub>R<sup>7</sup>;

f is 0, 1 or 2; and


each R<sup>7</sup> and each R<sup>8</sup> are the same or different and are each independently selected  
65 from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and  
cycloalkenyl; and

each R<sup>9</sup> is the same or different and is selected from H, halo and alkyl;  
or a pharmaceutically acceptable salt thereof.

44. (Previously Presented) An R-isomer of a compound according to claim  
43.

45. (Canceled)

46. (Previously Presented) A compound of formula (Ib):



wherein:

5 R<sup>1</sup> is -C(O)NH<sub>2</sub>;

each R<sup>9</sup> is the same or different and is selected from H, halo and alkyl;

Ring A is phenyl;

d is 0;

e is 1;

R<sup>6</sup> is trifluoromethyl;

n is 1 and Q<sup>2</sup> is at C-6;

R<sup>5</sup> is H;

5 f is 0, 1 or 2; and

each R<sup>7</sup> and each R<sup>8</sup> are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl; and


Q<sup>2</sup> is a group of formula:  $-(R^2)_{aa}-(Y^2)_{bb}-(R^2)_{cc}-R^4$ , wherein:

10 aa is 0;

bb is 0;

cc is 1 and (R<sup>2</sup>)<sub>cc</sub> is C<sub>1-3</sub>alkylene; and

R<sup>4</sup> is a group of formula (ii):



15 wherein:

Ring A is selected from the group consisting of morpholine, piperidine, piperazine, phenyl, pyrrolidinone, imidazolidinone and pyrrolidine

d is 0;

e is 1; and

20 R<sup>6</sup> is selected from the group consisting of H, halo, alkyl, =O, -OR<sup>7</sup>, -S(O)<sub>n</sub>R<sup>7</sup>, -S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup> and -NR<sup>7</sup>R<sup>8</sup>;

or a pharmaceutically acceptable salt thereof.